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Background: Corruption in the health sector can hurt health outcomes. Improving good governance can in turn
help prevent health-related corruption. We understand good governance as having the following characteristics: it
is consensus-oriented, accountable, transparent, responsive, equitable and inclusive, effective and efficient, follows
the rule of law, is participatory and should in theory be less vulnerable to corruption. By focusing on the
pharmaceutical system, we explore some of the key lessons learned from existing initiatives in good governance. As
the development community begins to identify post-2015 Millennium Development Goals targets, it is essential to
evaluate programs in good governance in order to build on these results and establish sustainable strategies. This
discussion on the pharmaceutical system illuminates why.
Discussion: Considering pharmaceutical governance initiatives such as those launched by the World Bank, World
Health Organization, and the Global Fund, we argue that country ownership of good governance initiatives is
essential but also any initiative must include the participation of impartial stakeholders. Understanding the political
context of any initiative is also vital so that potential obstacles are identified and the design of any initiative is
flexible enough to make adjustments in programming as needed. Finally, the inherent challenge which all initiatives
face is adequately measuring outcomes from any effort. However in fairness, determining the precise relationship
between good governance and health outcomes is rarely straightforward.
Summary: Challenges identified in pharmaceutical governance initiatives manifest in different forms depending on
the nature and structure of the initiative, but their regular occurrence and impact on population-based health
demonstrates growing importance of addressing pharmaceutical governance as a key component of the post-2015
Millennium Development Goals. Specifically, these challenges need to be acknowledged and responded to with
global cooperation and innovation to establish localized and evidence-based metrics for good governance to
promote global pharmaceutical safety.
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Global institutionsBackground
The potential for corruption to limit human develop-
ment has gained traction within the global development
community since then World Bank President James
Wolfensohn’s 1996 speech on the “cancer of corruption”
[1]. As the conversation on corruption has progressed,
attention has shifted to how it can be prevented, with an
emphasis on good governance. Since then, there have
been a number of important milestones, including most* Correspondence: jillian.kohler@utoronto.ca
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reproduction in any medium, provided the ornotably, promotion of good governance as a core elem-
ent in the post-2015 development agenda carrying for-
ward the United Nations Millennium Development
Goals (MDGs) [2].
Progress has also included the development of widely
accepted international binding norms recognizing the
importance of coordinating global action against forms
of corruption. In October 2003, the United Nations
General Assembly adopted the United Nations Conven-
tion against Corruption (UNCAC) under the United Na-
tions Office of Drugs and Crime. The UNCAC is an
international treaty instrument that specifically addresses
the prevention, criminalization, and mobilization ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activities. The engagement of diverse international orga-
nizations and civil society actors has been crucial in
highlighting the overall impact of corruption on devel-
opment and identifying broad strategies to address it [3].
However, to be successful, generally good governance
programs addressing corruption must be more focused
in their target areas. This often includes assessment of
diverse elements of both the public sector and the pri-
vate sector environment. In addition, sectors such as
health systems are highly complex and require tailored
governance approaches to identify potential risk factors
associated with corruption, waste, and fraud and abuse.
For example, the delivery of life-saving pharmaceutical
commodities requires specific training and knowledge
unique to this critical component of the global, national
and local health infrastructure. In order to inform future
efforts and establish better causality between good gov-
ernance initiatives and health outcomes in this sector,
careful examination and comparison of existing initia-
tives attempting to address this issue is essential. This
will ensure that future work in pharmaceutical good
governance is appropriately informed by evidence and
lessons learned, increasing the likelihood of continued
success and improvement.
Certain aspects of good governance may be mostly
relevant to lower and middle-income countries where
governance is deficient in national health systems. This
includes governance areas of maintaining regulatory im-
partiality, ensuring quality and safety of medicines in
manufacturing and procurement practices, and prevent-
ing undue pay-offs for health care services. Others are
highly relevant in high-income countries such as pre-
venting fraud and abuse and preventing illegal marketing
practices of pharmaceutical companies.
For example, the United States, the largest pharma-
ceutical market in the world, has experienced record
breaking criminal and civil fines associated with illegal
pharmaceutical marketing, including some USD$4 bil-
lion in recoveries in 2010 [4]. Illegal pharmaceutical
marketing in the United States has been uncovered by
whistle-blowers, likely helped by enabling U.S. legislation
that includes certain protections and incentives, and
have revealed practices that led to increased drug costs,
biasing or misrepresenting scientific evidence/education,
and direct risks to patient safety through illegal off-label
promotion [4,5]. This includes a recent settlement
against Johnson & Johnson of USD$2.2 billion for mis-
leading doctors about the safety of its antipsychotic
Risperdal [6,7]a. It also illuminates the importance of
structural changes that, if implemented and monitored,
ensure better governance. As an example, even though
we are finding an increase of physician-directed pharma-
ceutical marketing transparency laws internationally,continued violations and legal settlements indicate that
more rigorous governance initiatives may be needed [8].
As an initial commentary on existing governance ini-
tiatives in the pharmaceutical sector where the public
and private sphere often intersect, this paper identifies
three thematic areas whose effective management is es-
sential for success: authentic country ownership of good
governance initiatives, understanding about how the pol-
itical context may help or hinder an initiative, and moni-
toring and evaluating how good governance initiatives
may help improve health outcomes. We conclude with a
discussion on how international cooperation and shared
governance approaches that emphasize improvement in
these areas can promote global pharmaceutical safety
and advocate for their need in the future development of
the MDGs.
Importance of good governance in health
As a broad concept, good governance implies a system
which is consensus oriented, accountable, transparent,
responsive, equitable and inclusive, effective and effi-
cient, follows the rule of law, and is participatory [6,7].
Corruption, which is defined by the World Bank as the
“abuse of public office for private gain”, is assumed to be
more likely when good governance is not present al-
though establishing causality is not straightforward in
practice [8]. We use the World Bank’s definition for our
paper as we specifically examine why pharmaceutical
governance is important for equitable and efficient ac-
cess to medicines. While the focus of our paper is good
governance in the public sector and in international
agencies and development initiatives, we do acknow-
ledge the obvious importance of examining this issue in
the private sector as well. This includes additional
exploration of industry-specific prevention measures in
health governance mechanisms to improve transparency,
anti-corruption and anti-bribery tools, industry regula-
tion, and legal prosecution of illegal practices.
In order to better explore the relationship between
health governance and corruption, there is a clear need
for better data collection and agreed upon metrics to
support research and evidence-based policymaking. In
response, several organizations including the World
Bank, Transparency International, and the World Justice
Project have attempted to develop indicators and in-
dexes to better assist states in improving governance,
controlling corruption, assessing the rule of law, and
minimizing potential negative impact from these factors
in development projects. However, divergent institu-
tional approaches, varying indicators across organiza-
tions, and a lack of robust research addressing the
underlining relationship between governance and cor-
ruption, currently pose challenges to promoting anti-
corruption activities, especially in the health sector.
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creasing evidence that greater vulnerability to corruption
can lead to limiting access to medicines and health ser-
vices [3,9]. In Venezuela, for example, approximately
two-thirds of hospital personnel surveyed were aware of
theft of medical supplies and medications [10]. Similarly,
in Costa Rica, 71 per cent of doctors and 83 per cent of
nurses reported that equipment or materials had been
stolen in their hospital [11]. One study in Uganda found
that the resale of drugs represented the greatest single
source of income for health care personnel [12]. Another
study by Amnesty International on maternal health in
Burkina Faso found that one of the primary causes of
annual mortality in thousands of pregnant women (in-
cluding during childbirth) is due to corruption by health
professionals and poor healthcare delivery [13]. Poorer
women may also lack access to critical health care ser-
vices simply because they are unable to pay informal fees
[13]. Collectively, these case studies identify key forms of
corruption in the pharmaceutical and healthcare delivery
infrastructure, often exacerbated by a lack of financial
resources, poor remuneration of healthcare profes-
sionals, and the brain drain of healthcare workers [14].
However, identification and evaluation of health corrup-
tion may fail to explicitly measure key governance indi-
cators leading to a lack of evidence regarding the direct
relationship between lack of good governance and its
impact on enabling corrupt practices.
Conversely, evidence has also shown that good govern-
ance can improve key development goals; a study from
Transparency International demonstrated that increasing
transparency, accountability and integrity in 48 countries
had a robust correlation to better outcomes in health,
education and water access [15]. Another example is
program evaluation efforts by the Inter-American Devel-
opment Bank (IDB) that conducted an external audit of
public hospitals in Bogota, Colombia analyzing the
current situation of hospital finances, highlighting prob-
lematic areas, creating action plans to resolve issues un-
covered, and implementing a monitoring and evaluation
process with dissemination of information related to this
project through workshops. This external review pro-
vided Bogota’s Secretariat of Health with evidence that
fraud was taking place, and in response measures were
taken to reduce theft and improper billing in the hos-
pital setting [15]. Another clear example of how good
governance generates benefits is with pricing transpar-
ency. The public posting of medical supplies purchased
by public hospitals by the city government of Buenos
Aires, Argentina resulted in prices reductions within the
first few months of this intervention. Arguably, the mere
anticipation of price reporting/transparency helped lower
prices. Unfortunately the price declines were not main-
tained over time, suggesting the importance of designingmulti-prong anti-corruption strategies that reinforce these
selective responses over time [16].
Despite this growing recognition of the importance of
good governance in health, corruption continues to be
reported in national and global health systems across a
range of environments and has undermined progress in
health services delivery and system strengthening at a
time when investments in global health interventions
continue to be strong but also heavily scrutinized [4,17].
This includes a diversity of forms of health-related cor-
ruption in both the private and public sphere in high-
income countries, developed country settings, and in
multilateral initiatives. These forms of corruption have
yet to be effectively addressed through a global govern-
ance framework specific to health-related corruption or
pharmaceutical governance [4].
The need for good governance in the pharmaceutical
system
The efficient and safe selection, procurement, storage
and delivery of pharmaceutical commodities are essential
functions in ensuring sustained global health outcomes,
especially in resource-poor settings. Good governance
approaches and absence of corruption in both the public
and private pharmaceutical sector are crucial in main-
taining adequate distribution of essential medicines for
populations who lack access, preventing diversion/theft
of pharmaceuticals, protecting against illegal pharma-
ceutical promotion (e.g. illegal off-label promotion), and
ensuring that medicines are safe and not falsified
[18,19]. For instance, an example of industry conflicts of
interest is apparent in a recent decision made by a USA
Food and Drug Administration (FDA) Advisory Com-
mittee (with members that included those with ties to
the manufacturer of the oral contraception products
under review) to keep birth control pills Yaz and Yasmin
on the market, even though they were associated with
increasing patient adverse safety events.
In addition, with increasing prevalence and attention
to non-communicable diseases globally (highlighted by
the recent 2011 United Nations High-level Meeting on
Non-communicable Diseases) that often require sustained
pharmaceutical treatment, coupled with annual global
pharmaceutical spending that is forecasted to reach USD
$1.2 trillion by 2016, the integrity of the global pharmaceut-
ical supply chain is clearly important to the future of global
health [20]. Yet, despite this increasing need and rapid mar-
ket growth, pharmaceutical good governance in individual
countries has been markedly uneven globally.
When good governance is absent in the pharmaceut-
ical system, access to and quality of medicines are af-
fected [21]. Hence, good governance in pharmaceuticals
should ideally be a guiding principle to the operation of
the entire pharmaceutical supply chain and health
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context of ensuring progress is made towards reaching
the MDGs and as post-2015 targets are established. In
fact, recognition that good governance must be an es-
sential component of all programs focused on the health
system is necessary within the context of promoting ac-
cess to medicines as a human rights issue, a concept that
has been reinforced by resolutions and reports issued by
the UN General Assembly, UN Human Rights Council,
and World Health Organization (WHO).
Importantly, there is no single “prescription” to en-
trench good governance in the pharmaceutical sector.
The sector presents unique challenges: demand is often
greater than the supply, there is significant uncertainty
in how much of each product is needed, and the com-
plex globalized drug supply chain comprised of both
public and private sector actors has the potential for
market failure at each step. It is clear, however, that
these challenges cannot become excuses for inaction.
Rather, multiple approaches and possible global efforts
aimed at adapting to local requirements, while at the
same time attempting to achieve some measure of
harmonization in procurement and delivery for purposes
of efficiency, must continue to be explored. These steps
are necessary in order to enact effective change at the
national and global level informed by examination of
strengths and weaknesses of current pharmaceutical
governance initiatives.
E-procurement as done in the Chilean procurement
system is often cited as an effective tool to prevent cor-
ruption in drug procurement. Through the use of elec-
tronic bidding and information dissemination about
procurement procedures and results, corruption has
been curbed substantially. These anti-corruption inter-
ventions were even more effective when a wide range of
suppliers competed for each product openly so that
price competition was fostered and opportunities for
collusion were reduced [22]. Such examples of innova-
tive forms of governance and technology utilization
should be encouraged and incorporated into future
pharmaceutical governance initiatives and may have
shared value among stakeholders.
Current pharmaceutical governance efforts
Recognizing that good governance matters for improved
health outcomes and return on development invest-
ments, global institutions like the World Bank, the
WHO’s Good Governance for Medicines Programme
(GGM), the Global Fund for HIV/AIDS, Tuberculosis,
and Malaria (Global Fund), and the UK Department for
International Development (DFID) through the Medi-
cines Transparency Alliance (MeTA) have launched a
number of initiatives in the past decadeb. These pro-
grams have used a range of approaches, with varyinglevels of success but are primarily focused on low to
middle income country settings and public sector gov-
ernance improvements. Each initiative has now been in
operation for enough time that it is possible to provide a
preliminary review of their impacts and draw lessons for
future developmentc.
The World Bank
The World Bank has addressed good governance in a
number of ways and was an early pioneer of measuring
good governance in the pharmaceutical system by devel-
oping a tool to determine vulnerability to corruption in
2002. Currently, procurement practices are monitored
on a grant-by-grant basis whenever medicines purchases
are required [23]. Still, in 2007-2008, fraud and corrup-
tion were identified in procurement for a major project
in India [23]. This led to unintended negative conse-
quences. For example, policy discussions were signifi-
cantly hampered as well as investments in health
systems projects. However, more positively, these find-
ings of fraud and corruption solidified efforts by the
World Bank to improve its country-client procurement
practices [21]. The World Bank, however, is less focused
on anti-corruption interventions in the pharmaceutical
system per se but rather on broader health systems
strengthening projects, which may have a less discernible
result in terms of their specific impact on good govern-
ance in the pharmaceutical system.
WHO’s Good Governance for Medicines Programme
(GGM)
GGM, at the time of this writing has been in place in 36
countries; it emphasizes strengthening rules and proce-
dures within the supply chain and on instilling a long
term government commitment to good governance [24].
The program begins by assessing a country’s pharma-
ceutical system’s vulnerability to corruption, using a tool
based on one that was developed by the World Bank.
Based on the results, a plan to strengthen good govern-
ance is established and then implemented in partnership
with the national government. This model uses a fairly
rigid structure in the early stages of the project, measur-
ing all countries on the same criteria, but flexibility in-
creases as countries move through to the policy change
stages. Following a reassessment of countries (using the
same vulnerability to corruption methodology), it was
found that the improvements in good governance were
made predominately in registration, drug selection and
procurement and were less apparent in areas such as
clinical trials and marketing practices.
Medicines Transparency Alliance (MeTA)
In its pilot phase (2008-2010), MeTA was put in place
in seven countries (the Philippines, Zambia, Jordan,
Kohler et al. BMC Public Health 2014, 14:63 Page 5 of 8
http://www.biomedcentral.com/1471-2458/14/63Kyrgyzstan, Peru, Uganda and Ghana) [25]. Phase II
(2012-2016) is in place in the same countries, although
entry and exit criteria have been established to accom-
modate any future changes. MeTA emphasizes the
disclosure of information as a way to improve transpar-
ency, accountability, and ultimately access to medicines.
The premise of MeTA is that transparency is essential
for addressing corruption and that the movement to-
wards greater transparency would be more effective with
communication between representatives from the public
sector, private sector and civil society. This resulted in
the requirement for a number of disclosure surveys early
in the MeTA process and the establishment of a multi-
stakeholder group to lead the program in each country.
Beyond these core principles, MeTA’s structure is very
flexible, the establishment and implementation of work
plans is flexible and elected changes are often unique to
each country recognizing the need for unique local re-
quirements. Results from MeTA included the comple-
tion of baseline surveys and data disclosure, as well as
drug pricing policy changes.
The Global Fund
The Global Fund is a grant-making organization for pro-
jects targeting the Big Three diseases (HIV, TB, and Mal-
aria), supporting projects that will, in the long term,
prevent infections and improve access to treatment [26].
Given that procurement accounts for 40 per cent of
spending in Global Fund grants, ensuring that the prod-
ucts are of good quality and were purchased for the best
possible price is essential for the Global Fund’s program-
ming [21]. This has led to the establishment of Volun-
tary Pooled Procurement (VPP), allowing countries with
weaker systems to purchase quality assured medicines
through the Global Fund. Additionally, all purchases are
submitted to a database with documents demonstrating
that medicines are of good quality. While these mea-
sures have not completely prevented corruption in the
granting process, it must be recognized that funds that
have been identified as embezzled in subsequent investi-
gations represent a very small proportion of the total
grant portfolio. In 2010 the Global Fund’s own Inspector
General identified embezzlement in a number of coun-
tries, but the total amounted to USD$34 million out of a
total budget of USD$3 billion. With recent changes in
leadership there have been assessments of the Global
Fund’s procedures, and a comprehensive restructuring of
the granting process as well as a restructuring of its pro-
curement processes [27].
Discussion
Assessment of pharmaceutical governance initiatives
In addition to this discussion, a recent U4 Issue Paper
[21] identifies and assesses key global good governanceinitiatives in the pharmaceutical sector. It outlines a
number of “good enough” lessons, which can guide fu-
ture program development. We highlight a few of the
key ones here:
1. Donors need to promote political dialogue and
stakeholder consensus building throughout the
implementation of initiatives to agree on priority
areas within the pharmaceutical system as well as on
which tools are most effective to employ.
2. Granting institutions like the Global Fund and the
World Bank should leverage their resources by
providing funding to countries when good
governance is in place or when there is
demonstrated commitment to address governance
weaknesses and to withhold resources when these
conditions are not in place. Given that measuring
good governance is not yet a standard government
practice, this would likely require the development
of pre-approval analysis of pharmaceutical systems,
which should include both empirical measurements
and a broader consideration of the local regulatory
and political dynamics.
3. Monitoring and evaluation mechanisms need to be
an essential component of any governance initiative.
[There is a] need to move away from a reliance on
irregular surveys and move towards better use of
routine information and more “real” time sampling
methodologies that can generate data to inform
management decisions and sustain advocacy and
vigilance by community groups.
4. Country ownership of pharmaceutical good
governance initiatives is critical. This includes
political support, facilitation of a dialogue with a
range of local stakeholders and ensuring they are a
part of program development and implementation.
[This] has been an integral to the success of
countries such as Jordan and the Philippines, in both
GGM and MeTA. To be sure, it is complex and may
be more feasible in countries that have the political
and economic power to withstand any undue
influence.
5. Grant-making institutions should pay more attention
to making sustainable improvements in country
pharmaceutical supply systems and the regulatory
environment that governs them instead of [solely]
on the execution of individual grants (p. 21).
However, given the diversity of approaches to good
governance in the pharmaceutical system, systematic
comparisons across initiatives are inherently limited. Ac-
tivities are based in different institutions with distinct vi-
sions of how good governance ought to be implemented,
engaged different sets of stakeholders who were involved
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and measurements were made using different indicators.
Still, there are some core lessons that can ideally guide
more effective governance work in the pharmaceutical
system for the future.
To start, there is consistent evidence from all initia-
tives that country ownership, meaning in this context
that the government where the initiative is taking place
be genuinely committed to understanding what policy,
institutional, and cultural reforms are needed to make
good governance happen. It is also clear that multi-
stakeholder engagement is critical to success. For ex-
ample, the active participation of relevant stakeholders
in both GGM and MeTA allowed for strong results in
terms of establishing a dialogue and developing relations
and trust between previously disparate groups (public
sector, private sector, and civil society). In both of these
programs, the inclusive development of national plans to
improve governance was key, allowing those with the
closest ties to specific issues to help shape and have
ownership of the changes made. Granting institutions,
like the World Bank and Global Fund, have strengths in
these circumstances as funding can be tied to the com-
pletion of necessary changes and because of their broad
membership and partnership with non-state actors. For
example, the Global Fund’s new strategy specifically
states in relation to one of its stated goals that, “align-
ment with national strategies and systems is a key
principle of aid effectiveness, which contributes to en-
hanced country ownership, lower transaction costs,
greater financial transparency, increased mobilization of
multiple partners (including civil society) and sustain-
ability – and ultimately better impact [28]”.
Conversely, changes in government, a lack of cooper-
ation across relevant ministries, and unbalanced repre-
sentation of stakeholders (for example low participation
from civil society groups) are real challenges. This de-
pendency on commitment from political leadership
makes establishing sustainable programs and policies
more difficult and any future initiatives must recognize
that simply changing policies on paper is likely to be in-
sufficient. It further indicates that governance initiatives
must be supported with adequate transparency and rules
in relation to participation of stakeholders, the establish-
ment of formal and truly accountable cooperation mech-
anisms among parties, and work plans to address
possible programmatic or government changes. Cultural
shifts in how good governance is perceived may also be
necessary for changes to be effective even if accompan-
ied with needed changes in political commitment/
leadership.
The pharmaceutical system operates as a part of an
overarching and much more complex health system and
this is clearly recognized by the initiatives. As noted inthe case of the World Bank, pharmaceutical good gov-
ernance is commonly viewed as a component of health
systems strengthening programs. Cross-cutting consen-
sus on the direction of the program and making it pos-
sible to adjust for individual country contexts is critical.
It is unfortunately too common for global institutions to
evade the examination of uncomfortable but critical pol-
itical issues in the health sector, such as state, regulatory
and policy capture as well as the global policy context.
The resulting reality is that systemic change takes time,
capacity, and broad commitment to implement initia-
tives and to determine results from them. More focused
efforts on specific issues (e.g. drug registration, national
formulary inclusion, or public sector generic substitution
policies) can result in more rapid changes but may not
result in the deeper systemic shifts necessary to improve
overall system performance. The MeTA and GGM both
allow for significant flexibility in how policy changes are
determined, although there is more structure in GGM.
Global Fund grants are driven by country ideas and the
World Bank also shapes its programs based on the is-
sues identified in countries.
Another crucial area of needed improvement in
pharmaceutical governance initiatives is monitoring and
evaluation. It appears that monitoring of the results from
these initiatives has been relatively weak and may be in-
fluenced by the difficulty in adequately defining causal
relationships between good governance reforms and
health outcomes. There is an implicit assumption in the
programs that by strengthening the pharmaceutical sup-
ply chain and thereby improving its governance, de-
creased corruption and improved access to medicines
will result. The difficulty comes in identifying whether
this has occurred and if access has improved, and
whether it can be attributed to the improvements in
good governance instead of other external factors.
In addition, procurement and quality assurance are
two components of the supply chain where causality be-
tween reforms and health outcomes may be easier to
establish. Quantitative-driven results can be measured in
terms of reported pricing, the number of inspections
and the prevalence of falsified medicines (if such data is
available), and information about stock outs/availability
at point of delivery. It is also feasible to determine the
impact of changes such as conflict of interest policies
(i.e. in the selection of essential medicines or drug for-
mulary decisions) and deign studies to evaluate their
effectiveness on improving access and affordability. Yet,
monitoring and evaluation is essential if these reforms
are to have legitimacy as being necessary for the
strengthening of the pharmaceutical system and improv-
ing access to medicines. As evaluation procedures are
developed, they must consider how to structure indica-
tors to be informative about their actual impact on the
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vices, and at least to some extent the final health out-
comes. These measurements will unavoidably have
limitations, but while there is currently a dearth of infor-
mation on how to proceed with these steps, this work is
necessary if good governance reforms are to be estab-
lished and sustainable and if they are to be employed
more widely for the global pharmaceutical system.
Summary
The experiences with existing initiatives reveal that ef-
forts must be iterative, making changes when needed
and also shifting focus over time for local and inter-
national requirements of the globalized drug supply
chain. This is needed also in part because any change
will result in different incentives and new opportunities
for corruption that must be reassessed for vulnerability.
This flexibility will be an essential component to future
programs and long term goals for the establishment of
sustainable global institutions and ensuring safe and
equitable access to medicines.
Greater communication and cooperation between rele-
vant stakeholders engaged in pharmaceutical systems, in-
cluding development-granting institutions, international
organizations with good governance programs, the private
sector, and donor-aid recipients could support more inte-
grated programs. This includes attempting to establish glo-
bal norms on good pharmaceutical governance with the
overall goal of ensuring safe and affordable access to
medicines. It can also include potential harmonization of
governance indicators sensitive to local needs and monitor-
ing and evaluation instruments already developed by the
World Bank, WHO, DFID and the Global Fund informed
by tools and research developed by UNDP, U4 and other
organizations specifically promoting good governance in
pharmaceuticals.
Procurement systems can also be strengthened by le-
veraging efficiencies of the Global Fund VPP model and
others such as UNITAID, an international organization
focused on identifying innovative solutions for market
failures and improving access in low-income countries.
Encouraging development of innovative pooled procure-
ment and funding for pharmaceutical commodities has
the potential to help regulate and control industry driven
conflicts of interest and corruption, prevent imbalances
in access, trade and price negotiations, and better ensure
the quality and efficacy of medicines.
Finally, increased investment and commitment to good
governance in pharmaceutical programs should be a cru-
cial component of the post-2015 development agenda
and health system strengthening grants in order to
strengthen overall governance, improve development ef-
forts, end corruption, and ensure human health well-
being. Without these essential components and a clearinternational commitment to governance in pharmaceu-
ticals, ensuring positive outcomes in the future of global
health and development cannot be assured.
Endnotes
aThere are various other examples of pharmaceutical
companies practicing inappropriate marketing practices
in the United States.
bThese institutions and initiatives were examined be-
cause they have were focused specifically on pharmaceut-
ical good governance and also have been implemented
over a long enough period of time to generate lessons
learned.
cThese initiatives have also been the subject of a study
for U4 that we noted has informed this paper.
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